Dazoxiben: a pharmacological tool or clinical candidate?

作者: HM Tyler

DOI: 10.1111/J.1365-2125.1983.TB02101.X

关键词:

摘要:

参考文章(20)
L. A. Carlson, A. G. Olsson, PGE1 in lschaemic Peripheral Vascular Disease Springer Netherlands. pp. 39- 51 ,(1979) , 10.1007/978-94-011-7843-3_3
S Moncada, J R Vane, Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacological Reviews. ,vol. 30, pp. 293- 331 ,(1978)
A. Fry, Rupture of the Spleen BMJ. ,vol. 2, pp. 1031- 1031 ,(1951) , 10.1136/BMJ.2.4738.1031
Philip Needleman, Angela Wyche, Amiram Raz, Platelet and Blood Vessel Arachidonate Metabolism and Interactions Journal of Clinical Investigation. ,vol. 63, pp. 345- 349 ,(1979) , 10.1172/JCI109309
P C Clifford, M F Martin, E J Sheddon, J D Kirby, R N Baird, P A Dieppe, Treatment of vasospastic disease with prostaglandin E1. BMJ. ,vol. 281, pp. 1031- 1034 ,(1980) , 10.1136/BMJ.281.6247.1031
M Tada, T Kuzuya, M Inoue, K Kodama, M Mishima, M Yamada, M Inui, H Abe, Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris. Circulation. ,vol. 64, pp. 1107- 1115 ,(1981) , 10.1161/01.CIR.64.6.1107
P. J. Webb, J. Westwick, M. F. Scully, J. Zahavi, V. V. Kakkar, Do prostacyclin and thromboxane play a role in endotoxic shock British Journal of Surgery. ,vol. 68, pp. 720- 724 ,(2005) , 10.1002/BJS.1800681015